[68Ga]Ga-PentixaFor in Primary Aldosteronism: Billion-Dollar Potential in an Underserved Mass Market

Pentixapharm Holding AG today announced the positive feedback from the FDA ("study may proceed") for the initiation of the Phase III PANDA study with [68Ga]Ga-PentixaFor. Subject to successful development and regulatory approval, the company sees an annual revenue potential of over one...